Monti, Jan, Martina Schinke, Manfred Bö hm, Detlev Ganten, Michael Bader, and Giampiero Bricca. Glial angiotensinogen regulates brain angiotensin II receptors in transgenic rats TGR(ASrAOGEN). Am J Physiol Regulatory Integrative Comp Physiol 280: R233-R240, 2001.-TGR(ASrAOGEN)680, a newly developed transgenic rat line with specific downregulation of astroglial synthesis of angiotensinogen, exhibits decreased brain angiotensinogen content associated with a mild diabetes insipidus and lower blood pressure. Autoradiographic experiments were performed on TGR(ASrAOGEN) (TG) and Sprague-Dawley (SD) control rats to quantify AT 1 and AT 2 receptor-binding sites in different brain nuclei and circumventricular organs. Doseresponse curves for drinking response to intracerebroventricular injections of ANG II were compared between SD and TG rats. In most of the regions inside the blood-brain barrier [paraventricular nucleus (PVN), piriform cortex, lateral olfactory tract (LOT), and lateral preoptic area (LPO)], AT 1 receptor binding (sensitive to CV-11974) was significantly higher in TG compared with SD. In contrast, in the circumventricular organs investigated [subfornical organ (SFO) and area postrema], AT 1 receptor binding was significantly lower in TG. AT 2 receptors (binding sensitive to PD-123319) were detected at similar levels in the inferior olive (IO) of both strains. Angiotensin-binding sites sensitive to both CV-11974 and PD-123319 were detected in the LPO of SD rats and specifically upregulated in LOT, IO, and most notably PVN and SFO of TG. The dose-response curve for water intake after intracerebroventricular injections showed a higher sensitivity to ANG II of TG (EC 50 ϭ 3.1 ng) compared with SD (EC 50 ϭ 11.2 ng), strongly suggesting that the upregulation of AT 1 receptors inside the blood-brain barrier of TG rats is functional. Finally, we showed that downregulation of angiotensinogen synthesized by astroglial cells differentially regulates angiotensin receptor subtypes inside the brain and in circumventricular organs.
THE PRESENCE OF A SEPARATE and distinct renin-angiotensin system (RAS) within the brain has been documented for more than 20 years. ANG II receptors are expressed within the blood-brain barrier in discrete loci associated with cardiovascular, body fluid, and neuroendocrine regulation (17, 22) . Although the neuromodulatory role of ANG II starts to be well defined in vitro, a clear delineation between specific roles of circulating and intracerebral angiotensin active peptides is still a matter of debate, mostly because of the action of plasma RAS on the central nervous system through the circumventricular organs that lack the blood-brain barrier. Moreover, angiotensinogen is the only known ANG II precursor, and in the brain, glial cells are the major cell type expressing it, whereas ANG II is primarily of neuronal localization (3, 12, 15, 24, 26) . The mismatch in location of the various components of a brain angiotensin system has led to the concept of volume transmission (3) .
Very little is known about the factors involved in the regulation of brain ANG II receptors. In the periphery, an elevated ANG II level caused by sodium depletion or renal artery stenosis is associated with a diminished vasopressor response to intravenous infusion of ANG II related to a downregulation of the number of ANG II receptors. Conversely, reduced peripheral ANG II level by sodium loading or nephrectomy is associated with an enhanced vasoconstrictor response to peripheral administration of ANG II (7) .
As far as ANG II receptors in the brain are concerned, the role of ANG II in the regulation of its own receptors is controversial. Chronic subcutaneous infusion of ANG II in rats was shown to increase the number of ANG II binding sites in neuronal membranes from the diencephalon (33) . This effect would be indirect because ANG II does not cross the blood-brain barrier and would represent an action of ANG II on its receptor regulation in central structures opposite to that reported in the periphery. Other investigators reported that intracerebroventricular infusion of ANG II did not affect ANG II-receptor density or binding affinity in either the hypothalamus-thalamus-septummidbrain or the brain stem, and thus it was concluded that brain ANG II receptors are unresponsive to in-creased ANG II levels in the cerebrospinal fluid (25) . In the brain stem of angiotensinogen knockout mice, no change in AT 1 receptor mRNA was found, however, it was clearly upregulated in a variety of peripheral organs (27) .
TGR(ASrAOGEN) (TG) is a recently developed transgenic rat derived from Sprague-Dawley (SD) rats expressing an antisense RNA targeted against the 5Ј region of angiotensinogen mRNA under the control of the glial cell-specific glial fibrillary acidic protein promoter (23) . This leads to a colocalized expression of angiotensinogen antisense RNA and angiotensinogen RNA in glial cells, the major site of angiotensinogen synthesis in the brain (3, 26) . Angiotensinogen protein concentration determined by ELISA was reduced to ϳ10% in medulla, pons, hypothalamus, thalamus, and cerebellum compared with SD control rats. Angiotensinogen plasma concentrations and plasma renin activity were not affected as well as plasma sodium and potassium concentrations, indicating that the plasma renin-angiotensin-aldosterone system was not affected by the transgene (2, 23) . Basal systolic and diastolic blood pressure were significantly lower than in SD animals, and plasma vasopressin was decreased leading to diabetes insipidus (2, 23) .
Because the angiotensinogen decrease in TG occurs specifically in the brain, we expected a differential regulation of ANG II receptors in brain regions inside the blood-brain barrier and in circumventricular organs, which are accessible to circulating ANG II.
MATERIALS AND METHODS
Animals. Twelve-to-sixteen-week-old homozygous transgenic TG rats of the line 680 were kindly provided by Dr. Ursula Ganten (Max Delbrueck Center for Molecular Medicine, Berlin-Buch, Germany). SD Hanover rats were obtained from Moellegard Breeding & Research Center. This rat strain was the one used for the generation of the transgenic animals (23) . Rats were housed in single cages under controlled conditions (temperature: 23°C, light from 6 AM to 6 PM) and had free access to standard rat laboratory diet and tap water ad libitum. The studies were performed according to the Guiding Principles in the Care and Use of Animals, corresponding to American Physiological Society guidelines.
Tissue preparation and receptor binding. Rats were anesthetized with ether and intracardially perfused with ice-cold PBS, pH 7.4. Brains were removed, immediately frozen in isopentane at Ϫ30°C, and stored at Ϫ80°C. Coronal sections (thickness 12 m) were cut in a cryostat at Ϫ20°C and thaw-mounted on gelatin-coated cold glass slides. For each region of interest, we made three to five consecutive sets of six coronal slices and used the first and the last slices for conventional eosin staining.
Radioligand binding. Slide-mounted sections were thawed to room temperature and preincubated for 30 min at 22°C in 50 mM Tris ⅐ HCl buffer, pH 7.4, containing 150 mM NaCl, 5 Macintosh computer. Each region of interest was circumscribed manually; optical densities were measured, subsequently normalized with the 125 I-labeled standard curve and finally transformed into femtomole per milligram protein. All data are expressed as means Ϯ SE of three TG and four SD rats with three to five slices per region and per rat.
Intracerebroventricular ANG II injections. A detailed description for the procedure of stereotaxic injection in rats is given in Kawasaki et al. (10) . Briefly, while rats were under chloral hydrate anesthesia (4%), a stainless steel guide cannula (25 gauge) was inserted stereotaxically in the right lateral cerebral ventricle through a small hole drilled into the skull (1.4 mm lateral and 0.9 mm posterior to bregma and 4.5 mm below the skull) (16) . The cannula was fixed with jewelers' screws and dental cement and then closed with a dummy cannula. After surgery, rats were allowed to recover for 7 days. For each injection, the dummy cannula closing the implanted guide cannula was removed from the conscious rat; a 27-gauge internal cannula was inserted into the guide cannula and connected to a Hamilton 5-l microsyringe via a 30-cm polyethylene tube. Rats were allowed to accommodate for 1 h before ANG II dissolved in isotonic saline was injected at doses of (ng) 0.1, 1, 10, and 100 in random order with a total volume of 5 l. One injection only was given per day. Five microliters of isotonic NaCl vehicle were administered as control injections. The 3-h water intake was measured after each single injection. The basal unstimulated 24-h water intake was assessed for 2 days just before the first injection.
Statistics. Drinking responses to ANG II were compared between six TG and nine SD rats with the use of a two-way analysis of variance followed by post hoc analysis with the Newman-Keuls test. Dose-response curves were fitted to a four-parameter logistic equation with the Sigmaplot software. Fifty-percent effective dose (ED 50 ) and maximal effect were compared with an unpaired Student's t-test. Receptor densities and 24-h water intake were compared with the unpaired Student's t-test. All results are expressed as means Ϯ SE. The level for statistical significance was set at P Ͻ 0.05.
RESULTS
ANG II receptor-binding autoradiography. ANG II receptors were markedly expressed and discretely distributed in the adult rat brain. Nonspecific binding was Ͻ10% of total binding in all examined brain areas and most often reached the level of the background value of the film (Figs. 1, 2, 3, and 4) .
In all brain areas, the ANG II binding was consistent among the different brains studied. ANG II receptor binding was detected in the following brain areas: paraventricular nucleus (PVN), piriform cortex, median preoptic nucleus (MnPO), anteroventral preoptic nucleus (AVPO), lateral olfactory tract (LOT), lateral preoptic area (LPO), nucleus of the solitary tract (NTS), inferior olive (IO), subfornical organ (SFO), and area postrema (AP). In all regions of both TG and SD rats except the IO, binding was totally displaced by the AT 1 receptor antagonist CV-11974, i.e., it was not different from nonspecific binding as measured in the presence of both CV-11974 and PD-123319 (Table 1) . Total binding was significantly higher in all brain regions inside the blood-brain barrier in TG rats except in the NTS where total binding was significantly lower. Total binding was lower in the two circumventricular organs examined (SFO, AP) reaching statistical significance in the AP.
AT 1 binding sites were defined as CV-11974-sensitive binding sites. Conversely, AT 2 receptors were defined as PD-123319-sensitive and CV-11974-insensitive binding.
Except in the IO and MnPO where AT 1 receptor binding was similar and in the NTS where it was significantly lower, AT 1 receptor labeling was higher in all brain regions inside the blood-brain barrier of TG rats compared with SD controls. AT 2 binding could be detected only in the IO of both strains at similar levels ( Table 1) .
ANG II binding to receptors in circumventricular organs was measured in the AP and in the SFO (Figs.  2 and 4) . In both regions, AT 1 receptor binding was significantly lower in TG rats. AT 2 receptor binding could not be detected.
Unlike in the IO of both strains, in some regions of TG rats (LPO, PVN, LOT, SFO) and in the LPO region of SD rats, a significant amount of binding is PD-123319 displaceable and nevertheless also displaceable by CV-11974 (Table 1) .
Water and salt intake. The 24-h water intake in TG under basal conditions before intracerebroventricular injections was slightly elevated without reaching statistical significance (46.4 Ϯ 2.8 in TG vs. 40.8 Ϯ 3.6 ml/24 h in SD). In both rat strains, a dose-response curve to graded intracerebroventricular injections of ANG II was obtained (Fig. 5) . The dose response was significantly shifted to the left (P Ͻ 0.001) for TG. A four-parameter logistic fitting of the dose-response data confirmed the right shift with a significantly lower ED 50 in TG compared with SD control rats (3.12 Ϯ 1.4 ng vs. 11.2 Ϯ 5.4 ng, P Ͻ 0.05). The calculated basal, Emax, and slopes were similar for both strains (Fig. 5) .
DISCUSSION
Our results clearly show that in different forebrain areas inside the blood-brain barrier, the ANG II binding is significantly higher in AOGEN AS RNA-expressing transgenic rats compared with SD control rats.
Moreover, AT 1 receptor binding in the SFO and in the AP, which are both regions accessible to circulating ANG II, is downregulated compared with SD rats. The dose-response curve for drinking response to intracerebroventricular ANG II is significantly shifted to the left. These results allow us to conclude 1) decreased AOGEN synthesized by glial cells regulates neuronal AT 1 receptor expression, 2) glial cell-derived AOGEN regulates differentially AT 1 receptors inside the bloodbrain barrier and in circumventricular organs, and 3) the increased receptor labeling is paralleled by an increased drinking response to ANG II, strongly suggesting its functional significance.
The expression pattern of ANG II binding sites fits well to that determined in other quantitative autoradiographic studies. Those structures that were shown to mediate the major ANG II effects in body fluid homeostasis and cardiovascular regulation (PVN, SFO, AP, NTS, MnPO) contain almost exclusively AT 1 receptors, which is consistent with a number of autoradiographic studies (19, 29, 30) . The IO is the only structure where significant ANG II binding could be observed in the presence of CV-11974. Again, this is in line with other autoradiographic experiments (18) (19) (20) 29) . It should be mentioned that different autoradiographic studies found varying relative amounts of ANG II binding in different brain regions that seem to depend also on the radioligand used (34) .
Almost all examined forebrain areas exhibit higher ANG II binding in TG compared with SD rats, whereas ANG II binding in circumventricular organs is decreased in both the SFO and AP. Whether the variations in receptor labeling result from variations in receptor density or receptor affinity cannot definitely be clarified with the data obtained in this set of experiments. Nevertheless, the use of the ANG II antagonist So far, the reports of regulation of central ANG II receptors by ANG II are controversial. Although chronic subcutaneous infusion of ANG II in rats has been shown to increase the number of ANG II binding sites in neuronal membranes from the diencephalon (32), it can be argued that an upregulation of central ANG II receptors by circulating ANG II might be, in part, interpreted as a secondary phenomenon after increased aldosterone release (22) , because mineralocorticoids induce an increase in the number of ANG II receptors in discrete brain regions (11, 33) . Intracerebroventricular infusion of ANG II over 6 days (500 ng ⅐ l Ϫ1 ⅐ h
Ϫ1
) has been reported not to affect central ANG II receptor expression (25) , but again it can be speculated that with a dose of 500 ng ⅐ l Ϫ1 ⅐ h Ϫ1 , ANG II leaks into the peripheral circulation and would thereby stimulate aldosterone release. Aldosterone can cross the blood-brain barrier, and there, as discussed above, it is assumed to upregulate ANG II receptors that would interfere with the direct effects of the intracerebroventricularly infused ANG II. Moreover, the very high nonphysiological doses used in these studies should have increased blood pressure and possibly opened the blood-brain barrier. In conclusion, to our knowledge, this is the first study demonstrating that binding to brain ANG II receptors is regulated by angiotensin generated from glial cell-derived angiotensinogen.
The decrease in ANG II binding in the AP and SFO is unexpected. Because it was shown that the circulating components of the RAS are not altered in the TG rats (2, 23) , these alterations in receptor labeling can only result from the decreased brain angiotensinogen. It can thus be postulated that central angiotensinogen exerts a positive regulation on AT 1 receptor binding in these regions.
Interestingly, in four forebrain regions (LPO, PVN, LOT, SFO) in TG, 20 to 40% of the total binding can be inhibited by both CV-11974 and PD-123319, whereas such a phenomenon is only marginally found in the LPO region of the SD. This might be due to a loss of selectivity due to the high concentration of competitors. But there are reports about central and peripheral pharmacological effects of ANG II being inhibited by both AT 1 and AT 2 antagonists that were interpreted either as a permissive effect of AT 2 receptors on the binding of ANG II to AT 1 receptors (6, 13, 21, 28) or an action of PD-123319 through the AT 1B ANG II receptor subtype (5, 14) . However, this observation, which implies a modification of the selectivity of the receptors in the transgenic animals, requires further experiments to be clarified.
Graded intracerebroventricular injections of ANG II were followed by a significant dose-dependent increased drinking response in TG compared with SD rats. The increased drinking response to intracerebroventricular ANG II administration correlates very well with the observed upregulation of AT 1 receptors inside the blood-brain barrier in TG. Brain regions characterized by a higher expression of AT 1 receptors, like the MnPO, have been shown to be involved in the ANG II-mediated induction of thirst (9, 17) . Because the SFO AT 1 receptors can also participate in this response, their decreased expression in the TG rats can prevent part of this increased drinking response to intracerebroventricular ANG II. Thus it seems very likely that the demonstrated upregulation of AT 1 receptors in different brain regions of the forebrain is responsible for the enhanced responsiveness of neural circuits controlling water intake to ANG II, and it counteracts the decreased binding in the SFO region. Previous studies in spontaneously hypertensive rats (SHR) have demonstrated an attenuation of the elevated water and salt intake and decreased blood pressure after prevention of local ANG II formation with intracerebroventricular infusion of captopril or antisense oligonucleotides directed toward angiotensinogen or AT 1 receptor mRNAs (4, 8, 31) . The decreases in blood pressure as well as water and salt intake in these experiments were achieved by blocking the endogenous central RAS, supporting the view that centrally generated ANG II is a main factor leading to high blood pressure and exaggerated salt appetite in SHR. In normotensive Wistar-Kyoto and SD rats, there is also evidence for a role of central ANG II in drinking behavior. Intracerebroventricular injections of ANG II or renin caused increased salt appetite and drinking of water. Both renin-induced intakes were diminished by intracerebroventricular injection or infusion of angiotensin-converting enzyme inhibitors captopril or saralasin (1) , indicating that the renin-induced effects on water and salt intake are mediated mainly by ANG II.
It can be concluded that the observed hypersensitivity to intracerebroventricular administered ANG II in TG is a consequence of the decreased central synthesis of angiotensinogen as the only known precursor of ANG II in vivo (22) and the resulting upregulation of AT 1 receptors in the brain regions inside the bloodbrain barrier.
Perspectives
With the use of transgenic rats with a brain-specific inhibition of angiotensinogen expression, we have addressed a specific aspect of the still unsolved question whether the brain RAS works independently from the circulating RAS or whether it is mainly regulated by peripheral angiotensins acting via circumventricular organs. The very clear differentiation between upregulated AT 1 receptors inside the brain and nonaffected or downregulated AT 1 receptors in circumventricular organs is a strong argument for the hypothesis of an independent brain RAS in the control of fluid homeostasis. Moreover, the fact that angiotensinogen originating from glial cells modulates ANG II receptors in neurons argues in favor of the proposed volume transmission operating in the brain (3). Future experiments will have 1) to define more precisely whether only AT 1 or also other ANG II receptor subpopulations are subject to regulation by brain-borne angiotensinogen and 2) to clarify the meaning of our observation of ANG II binding sites sensitive to both CV-11974 and PD-123319. The transgenic animals with specific knock down of brain angiotensinogen used in this study can be a suitable tool to address these questions.
